<DOC>
	<DOCNO>NCT00441090</DOCNO>
	<brief_summary>The purpose study determine efficacy , safety tolerability , AKR-501 tablet , compare placebo , treatment patient chronic Idiopathic Thrombocytopenic Purpura ( ITP ) .</brief_summary>
	<brief_title>Study AKR-501 Tablets Taken Orally Once Daily 28 Days Patients With Chronic Idiopathic Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description>This Phase 2 , multi-center , double-blind , randomize , placebo-controlled , dose-ranging , parallel-group study . The PK PK/PD relationship AKR-501 also study . Approximately 65 eligible patient randomize 3:3:3:3:1 ratio double-blinded fashion one five parallel treatment group receive daily dos either AKR-501 2.5 , 5 , 10 20 mg placebo 28 day , respectively . Each AKR-501 dosing group consist 15 patient placebo group consist 5 patient . All study patient evaluate weekly ( Days 3 , 5 , 7 , 14 , 21 28 ) safety , efficacy , ( Days 7 , 14 , 21 , 28 ) AKR-501 pharmacokinetics receive study treatment final assessment safety effectiveness do 2 week last study dose ( Day 42 ) . At completion Visit Day 28±1 , patient complete 28±1 day study dose assess eligibility enroll rollover Study 501-CL-004 base visit .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Men woman ≥ 18 year age . 2 . Confirmed diagnosis ITP accord American Society Hematology ( ASH ) Guidelines ≥ 3 month prior Day 1 . 3 . If ≥ 60 year old , must either bone marrow biopsy consistent ITP within past 3 year good response ( platelet count &gt; 100,000/mm^3 ) previous ITP treatment . 4 . Are refractory relapse least one prior ITP therapy ( patient refractory fail achieve platelet count ≥ 50,000/mm^3 despite steroid ≥ 30,000/mm^3 prior ITP therapy , splenectomy , danazol , immunosuppressive drug . For patient relapse , platelet count must 50,000/mm^3 use steroid 30,000/mm^3 prescribed steroid . ) 5 . Patients receive maintenance corticosteroid may enrol , long corticosteroid administer stable dose ( milligram amount ± 10 % ) ≥ 2 week prior Screening Visit A investigator foresee need change steroid dose study participation . Patients remain stable corticosteroid dose study participation . 6 . Patients receive stable dosage cyclosporine A , mycophenolate mofetil , azathioprine danazol may also enrol . The dosages medication must stable least 3 month prior AKR501 administration . 7 . Platelet count : Patients receive steroid ( steroid treatment &gt; 2 week prior Screening Visit A ) : platelet &lt; 30,000/mm^3 Screening Visit A within 96 hour prior Day 1 ( Screening Visit B ) Patients receive steroid : platelet &lt; 50,000/mm^3 Screening Visit A within 96 hour prior Day 1 ( Screening Visit B ) . 8 . Women childbearing potential must negative pregnancy test Screening Visit A Screening Visit B . ( Childbearing potential define woman surgically sterilize premenopausal perimenopausal i.e. , menstrual flow within 12 month Screening Visit A ) . 9 . Women childbearing potential men must agree practice medically approve form contraception ( one follow must use : condom ( male female ) spermicidal agent , diaphragm , cervical cap spermicidal agent , IUD , hormonal contraception , abstinence ) . 10 . Willing able provide write informed consent studyrelated procedure . 1 . Women pregnant and/or lactating . 2 . Splenectomy procedure perform 4 week prior AKR501 administration . 3 . Use follow drug treatment prior Day 1 : Within 3 month Rituximab ; Within 2 week Aspirin Aspirincontaining compound , Salicylates , Anticoagulants , clopidogrel , ticlopidine , Rh0 ( D ) Immune Globulin ( WinRho® ) , intravenous immunoglobulin ( IVIG ) . 4 . Participation clinical trial involve investigational agent within 4 week Day 1 . 5 . Exposure eltrombopag AMG 531 . 6 . Significant medical condition disease determine Investigator ( e.g. , clinically active systemic lupus erythematosus ; know suspect HIV infection ; acute hepatitis clinically active chronic hepatitis ; lymphoproliferative disease ; congestive heart failure ) . 7 . History cardiovascular disease ( e.g. , angina , unstable angina , myocardial infraction , coronary artery stent placement , angioplasty , coronary artery bypass graft ) . 8 . History thromboembolic disease ( e.g. , transient ischemic attack [ TIA ] , stroke [ CVA ] , pulmonary embolism [ PE ] ) . 9 . History deep venous thrombosis ( DVT ) . 10 . History lupus anticoagulant anticardiolipin antibody syndrome positive anti b2 glycoprotein antibody . 11 . History medical condition systemic anticoagulation require 6 month . 12 . Laboratory abnormality : Hemoglobin &lt; 12.5 g/dL men &lt; 11.5 g/dL woman . If anemia clearly related ITP , example excessive blood loss , patient may enrol without need waiver discussion Sponsor 's medical monitor White blood cell count ( WBC ) &lt; low limit normal Absolute neutrophil count ( ANC ) &lt; 1000/mm^3 Prothrombin time ( PT ) &gt; 1.25 x upper limit normal Partial thromboplastin time ( PTT ) &gt; 1.25 x upper limit normal Total bilirubin &gt; 3 x upper normal limit Alanine transaminase ( ALT ) &gt; 3 x upper normal limit Aspartate transaminase ( AST ) &gt; 3 x upper normal limit Creatinine &gt; 1.5x upper normal limit Blood urea nitrogen ( BUN ) &gt; 1.5 x upper normal limit HIV positive IgM HAV positive , Hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( HCV ) positive . 13 . History , current alcohol drug abuse likely interfere ability comply protocol . requirement give informed consent , determine Investigator . 14 . History , current psychiatric illness likely interfere ability comply protocol requirement give informed consent , determine Investigator . 15 . Currently take follow medication : Rituximab , Aspirin Aspirincontaining compound , Salicylates , Anticoagulants , clopidogrel , ticlopidine , Rh0 ( D ) Immune Globulin ( WinRho® ) , intravenous immunoglobulin ( IVIG ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Chronic Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>ITP</keyword>
</DOC>